drugset / Trial / NCT00668005

Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction and Hypertension

NCT00668005

Phase 3 Completed 388 enrolled Bayer GlaxoSmithKline · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Assess efficacy of Vardenafil in patients erectile dysfunction and high blood pressure

Timeline

Start
2003-02
Primary completion
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Vardenafil Small molecule 5 mg
Subject Vardenafil Small molecule 10 mg
Subject Vardenafil Small molecule 20 mg

Indications